BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (Nasdaq: BBIO) reported equity inducement grants under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Pharma (Nasdaq: BBIO) reported equity inducement grants under Nasdaq Listing Rule 5635(c)(4). On June 18, 2026, the board’s compensation committee approved restricted stock unit awards covering 66,810 shares of common stock for 30 new employees.
One-fourth vests on May 16, 2027, with the remainder vesting quarterly, subject to continued employment. The awards were granted under a plan adopted in November 2019 and amended in February and December 2023.
Positive
- Inducement grants of 66,810 RSU shares to attract 30 new employees
- Structured vesting schedule supports employee retention over multiple years
Negative
- Potential shareholder dilution from issuance of 66,810 additional common shares
Details
News Market Reaction – BBIO
On Jun 24, the first trading day after this news, BBIO closed 1.06% above the previous close.
Data tracked by StockTitan Argus for the Jun 24 session.
Key Figures
- New employees
- 30 employees
- Recipients of inducement restricted stock unit grants approved June 18, 2026
- Inducement RSUs
- 66,810 shares
- Aggregate common stock underlying inducement restricted stock units
- Initial vesting date
- May 16, 2027
- One-fourth of RSU shares vest on this date, subject to continued employment
- Plan adoption
- November 2019
- Equity incentive plan adopted by BridgeBio’s board of directors
- Plan amendments
- February 10, 2023 and December 13, 2023
- Dates the equity plan was amended and restated
Historical Context
-
FDA accepted and granted Priority Review to BBP-418 NDA for LGMD2I/R9.
-
Submitted NDA for encaleret for ADH1 after successful Phase 3 CALIBRATE trial.
-
New Phase 3 acoramidis data showed disease-modifying effects in ATTR-CM.
-
Approved 115,007 RSUs as inducement grants for 52 new employees.
-
Reported Q1 2026 results and authorized a $500M share repurchase program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on June 18, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 30 new employees in restricted stock units for an aggregate of 66,810 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates.
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.